NDA 200603 · Sunovion Pharms INC
Latuda
Lurasidone Hydrochloride · Oral
NovelLast checked: Nov 20, 2026Latest source record: Jan 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Oct 28, 2010
Approved uses
7
Original approval plus efficacy supplements
Registered trials
85
41 Phase 3, 4 recruiting
FAERS reports
20,965
9,380 serious, 581 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. LATUDA is not approved for the treatment of patients with dementia-related psychosis ( 5.1 ). Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients. Closely monitor for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.2 ). Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of...
What it is approved for
From the label in effect Jan 31, 2025.
LATUDA is indicated for: Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia [see Clinical Studies ( 14.1 )] . Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies ( 14.2 )] . Adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies ( 14.2 )] . LATUDA is an atypical antipsychotic indicated for the treatment of: Schizophrenia in adults and adolescents (13 to 17 years) ( 1 , 14.1 ) Depressive episode associated with Bipolar I Disorder (bipolar depression) in adults and pediatric patients (10 to 17 years) as monotherapy ( 1 , 14.2 ) Depressive episode associated with Bipolar I Disorder (bipolar depression) in adults as adjunctive therapy with lithium or valproate ( 1 , 14.2 )
Mechanism: The mechanism of action of lurasidone in the treatment of schizophrenia and bipolar depression is unclear. However, its efficacy in schizophrenia and bipolar depression could be mediated through a combination of central dopamine D 2 and serotonin Type 2 (5HT 2A ) receptor antagonism.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 5, 2018 Supplement 29 · Efficacy LabelLetterPediatric CDTL Review
- Jan 27, 2017 Supplement 26 · Efficacy · priority review LetterLabelPediatric Medical Review
- Jan 27, 2017 Supplement 27 · Efficacy · priority review LetterLabelPediatric Medical Review
- Jun 28, 2013 Supplement 11 · Efficacy LabelReviewLetter
- Jun 28, 2013 Supplement 10 · Efficacy LabelReviewLetter
- Apr 26, 2012 Supplement 5 · Efficacy LabelLetter
- Oct 28, 2010 Original approval · Type 1 - New Molecular Entity NovelReviewSummary ReviewPediatric Medical Review
5 products under this application
- LATUDA · LURASIDONE HYDROCHLORIDE 120MG · TABLET, ORAL · Prescription · TE AB
- LATUDA · LURASIDONE HYDROCHLORIDE 80MG · TABLET, ORAL · Prescription · TE AB
- LATUDA · LURASIDONE HYDROCHLORIDE 60MG · TABLET, ORAL · Prescription · TE AB
- LATUDA · LURASIDONE HYDROCHLORIDE 20MG · TABLET, ORAL · Prescription · TE AB
- LATUDA · LURASIDONE HYDROCHLORIDE 40MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Lurasidone" as an intervention, any sponsor and status, largest first.
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
NCT05480150 · 10,000 participants (planned) · Start Nov 1, 2021 · Primary completion Dec 31, 2026
Drug: Escitalopram Oxalate Tablets; Quetiapine Fumarate Tablets and 1 more · For: Major Depressive Disorder; Bipolar Disorder, Mixed; Affective; Disorder, Organic
Sites: Hangzhou, China
- Sequential Multiple Assignment Randomized Trial for Bipolar DepressionPivotal-lookingActive, not recruiting
Massachusetts General HospitalAcademic, hospital or other
NCT06433635 · 2,726 participants (planned) · Start Oct 1, 2024 · Primary completion Feb 28, 2030
Drug: Cariprazine; Aripiprazole/Escitalopram combination and 2 more · For: Bipolar I Disorder; Depression
Sites: Birmingham, Alabama; Bloomington, Indiana; Baltimore, Maryland · 18 sites in all
- Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or DivalproexPivotal-lookingCompleted
Sumitomo Pharma America, Inc.Industry
NCT01358357 · 965 participants · Start Jun 2011 · Primary completion Apr 2015
Drug: Lurasidone; Placebo · For: Bipolar I Disorder
Sites: Dothan, Alabama; Glendale, California; Los Angeles, California · 105 sites in all
- Lurasidone - A 24-week Extension Study of Patients With Bipolar I DepressionPivotal-lookingCompleted
Sumitomo Pharma America, Inc.Industry
NCT00868959 · 817 participants · Start Apr 2009 · Primary completion Feb 2013
Drug: lurasidone · For: Bipolar Depression
Sites: Little Rock, Arkansas; Anaheim, California; Chino, California · 151 sites in all
- Pediatric Open-Label Extension StudyPivotal-lookingCompleted
Sumitomo Pharma America, Inc.Industry
NCT01914393 · 702 participants · Start Sep 30, 2013 · Primary completion Oct 17, 2018
Drug: Lurasidone 20, 40, 60, 80 mg, flexibly dosed · For: Schizophrenia; Autism; Bipolar Depression
Sites: Dothan, Alabama; Downey, California; San Francisco, California · 88 sites in all
- PEARL Schizophrenia MaintenancePivotal-lookingCompleted
Sumitomo Pharma America, Inc.Industry
NCT01435928 · 676 participants · Start Sep 2011 · Primary completion Aug 2013
Drug: Lurasidone; Matching Placebo · For: Schizophrenia
Sites: Springdale, Arizona; Little Rock, Arkansas; Cerritos, California · 75 sites in all
- Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable SchizophreniaPivotal-lookingCompleted
Sumitomo Pharma America, Inc.Industry
NCT00641745 · 629 participants · Start Mar 2008 · Primary completion Jul 2010
Drug: Lurasidone HCl; Risperidone · For: Schizophrenia; Schizoaffective Disorder
Sites: Little Rock, Arkansas; Anaheim, California; Cerritos, California · 73 sites in all
- A Phase III Study of SM-13496 in Patients With Bipolar I Depression.Pivotal-lookingCompleted
Sumitomo Pharma Co., Ltd.Industry
NCT01986101 · 525 participants · Start Feb 19, 2014 · Primary completion Feb 1, 2017
Drug: Placebo; SM-13496 and 1 more · For: Bipolar Depression
Sites: Tokyo, Japan; Kaunas, Lithuania; Kuala Lumpur, Malaysia · 8 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use2,089
- drug ineffective1,897
- anxiety1,241
- feeling abnormal1,170
- depression1,146
- weight increased1,104
- somnolence1,081
- nausea1,061
- insomnia1,016
- suicidal ideation1,011
- fatigue954
- dyskinesia832
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 102 |
| 2012 | 234 |
| 2013 | 229 |
| 2014 | 413 |
| 2015 | 745 |
| 2016 | 1,036 |
| 2017 | 2,654 |
| 2018 | 2,711 |
| 2019 | 3,110 |
| 2020 | 2,319 |
| 2021 | 2,827 |
| 2022 | 1,830 |
| 2023 | 1,066 |
| 2024 | 740 |
| 2025 | 545 |
| 2026 | 402 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Latuda (Lurasidone HCl)
2024 spending
$39.6M
Beneficiaries
6,273
24,193 claims
Per beneficiary
$6,320
$48.06 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,316,735,101 |
| 2021 | $1,366,288,474 |
| 2022 | $1,448,336,647 |
| 2023 | $455,168,823 |
| 2024 | $39,642,924 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.
Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. · Lancet 2019 · Research Support, Non-U.S. Gov't, Systematic Review
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
Leucht S, Cipriani A, Spineli L, et al. · Lancet 2013 · Comparative Study, Meta-Analysis
- Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2021 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Leucht S, Crippa A, Siafis S, et al. · Am J Psychiatry 2020 · Meta-Analysis
- Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis.
Pillinger T, McCutcheon RA, Vano L, et al. · Lancet Psychiatry 2020 · Comparative Study, Network Meta-Analysis
- Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis.
Yildiz A, Siafis S, Mavridis D, et al. · Lancet Psychiatry 2023 · Systematic Review, Network Meta-Analysis
Sponsor: Sunovion Pharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.